Altris.AI
Altris.AI is a Chicago-based medical AI company that provides an FDA-cleared, vendor-neutral cloud platform (Altris IMS) for storing and analyzing OCT retinal scans, using deep-learning models trained on 5 million scans to detect 30+ pathologies and 40+ biomarkers for ophthalmology clinics, optometry practices, and pharmaceutical research customers.
- Company typePrivate
- Founded2018
- HeadquartersChicago, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Altris.AI does
Altris.AI is a US-incorporated medical AI company headquartered in Chicago, Illinois, with technology R&D centers in Ukraine and Spain and an affiliated ophthalmic clinic in Spain. Founded in 2017, the company builds a vendor-neutral, cloud-based Image Management System (Altris IMS) for Optical Coherence Tomography (OCT) scans, combined with deep-learning models that detect and quantify retinal pathologies and biomarkers. The AI suite covers 30+ retinal pathologies and 40+ biomarkers, including Dry AMD, Wet AMD, Geographic Atrophy (GA), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), fluid-related conditions, and glaucoma features, with specialized research-use modules for each therapeutic area. The platform ingests DICOM and non-DICOM scans from 9 major OCT manufacturers (Canon, Heidelberg Engineering, Nidek, Optos, Optopol, Topcon, Visionix, Zeiss, and one additional) and provides automatic 10-layer retinal segmentation with thickness mapping, longitudinal progression analytics, and structured research outputs.
Altris serves three primary customer segments: ophthalmology clinics and optometry practices that need workflow support for OCT interpretation, pharmaceutical companies running ophthalmic clinical trials, and academic research institutions conducting large-scale retina research. The product is positioned as research-use decision-support rather than a diagnostic device, and the company cites 500+ eye care businesses using the platform across 34 countries as well as a 40,000-scan research collaboration with FinnGen and the University of Helsinki. The platform operates on GCP infrastructure with US and EU regions and is FDA 510(k) Class II cleared, CE marked, ISO 13485 certified, Health Canada approved, HIPAA-aligned as a Business Associate, and GDPR compliant.
The business model is a tiered subscription SaaS with a 14-day self-serve free trial, complemented by enterprise customization services such as private cloud deployment and API/PACS integrations. Go-to-market blends product-led growth (free trial, demo accounts) with inside sales for mid-market accounts and field sales for large eye care chains and pharmaceutical customers. An affiliate program (Ape Reach, 35% commission) extends low-cost distribution. The company has disclosed $1M in seed funding led by Runa Capital in December 2022, with subsequent undisclosed rounds involving Digital Future and Network.VC through 2024. Key leadership includes founder and CEO Andrey Kuropyatnyk and Chief Medical Officer Maria Znamenska (PhD in Ophthalmology, 16+ years of OCT experience).
Altris.AI firmographics
Firmographics- Name
- Altris.AI
- Legal name
- Altris, Inc.
- Website
- https://altris.ai
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Altris.AI is a Chicago-based medical AI company that provides an FDA-cleared, vendor-neutral cloud platform (Altris IMS) for storing and analyzing OCT retinal scans, using deep-learning models trained on 5 million scans to detect 30+ pathologies and 40+ biomarkers for ophthalmology clinics, optometry practices, and pharmaceutical research customers.
- Ownership category
- akta.pro rank
Altris.AI industry classification
Industry- Product category
- Ophthalmology AI Imaging Software
- NAICS
- Software Publishers (5132), Diagnostic Imaging Centers (621512)
- SIC
- Laboratory Analytical Instruments (3826), Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
Keywords
Where Altris.AI is headquartered
LocationHeadquarters
- HQ city
- Chicago
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Altris.AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations
Revenue model
- Subscription-based SaaS: Altris IMS is offered as a cloud-based subscription service with tiered plans based on usage volume. Eye care businesses and research institutions subscribe to access the platform's OCT analysis capabilities. 14-day free trial available before subscription commitment.
- Enterprise Customization Services: Customization services for larger businesses including private cloud deployment for additional data protection, API integrations with clinical systems, and PACS integration. These are offered as add-on services to enterprise subscribers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Pay-as-you-go | 14-Day Free Trial - Self-service exploration of platform capabilities |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels8 records
Altris.AI product offering
Product offeringCore offering
Altris.AI develops and sells Altris IMS, an FDA 510(k)-cleared, vendor-neutral cloud-based image management system for Optical Coherence Tomography (OCT) scans. The platform applies deep learning AI models trained on 5 million OCT scans to detect 40+ retinal biomarkers and 30+ retinal pathologies, providing quantitative measurements, longitudinal progression tracking, and vendor-neutral support for scans from 9 major OCT manufacturers. It is offered as a SaaS subscription targeted at eye care clinics, optometry practices, pharmaceutical clinical trial sponsors, and academic research institutions.
Product overview
Altris.AI offers a platform-plus-modules architecture centered on Altris IMS, an FDA-cleared vendor-neutral image management system for OCT scans. The core platform provides AI-powered analysis supporting 30+ retinal pathologies and 40+ biomarkers, with specialized ROU (Research Use Only) models for different therapeutic areas. The product portfolio includes three main market-facing configurations: Altris IMS for Ophthalmology, Altris IMS for Optometry, and Altris IMS for Pharma, each tailored to the specific workflow needs of eye care professionals, clinical researchers, and pharmaceutical companies conducting clinical trials. Specialized research modules cover Geographic Atrophy, Wet AMD, Dry AMD, Diabetic Retinopathy, Fluids, and Glaucoma, providing targeted AI capabilities for each condition. An educational application, Altris Education OCT, supports training for eye care specialists.
Differentiator
Problem solved
Functional benefit
Brands
- Altris Education OCT: Mobile application for interactive education on OCT interpretation for eye care professionals
- Altris IMS
Products and services
- Altris IMS (Image Management System) FDA-cleared, vendor-neutral cloud-based image management system for storing, organizing, and analyzing OCT scans from 9 major manufacturers (Canon, Heidelberg Engineering, Nidek, Optos, Optopol, Topcon, Visionix, Zeiss). Provides AI-powered detection of 40+ biomarkers and 30+ retinal pathologies with quantitative measurements and longitudinal tracking, offered as a SaaS subscription to eye care clinics, optometry practices, pharma sponsors, and research institutions.
- Altris IMS for Ophthalmology Specialized configuration of the Altris IMS platform tailored for ophthalmologists and ophthalmic clinics. Includes automated comparison of OCT features across multiple visits via percentage-based displays, maps, and graphs, and supports research workflows on 30+ retinal pathologies and 40+ biomarkers. For research use only.
- Altris IMS for Optometry Configuration of Altris IMS tailored to optometry practices, providing tools to visualize, quantify, and monitor 30+ retinal pathologies and 40+ biomarkers on OCT images. Enables vendor-neutral OCT analysis across 9 manufacturers and supports clinical decision-making in optometric workflows.
- Altris IMS for Pharma Research-focused configuration of Altris IMS for pharmaceutical companies conducting ophthalmic clinical trials and drug development research. Supports site eligibility workflows, biomarker analytics, treatment pattern analysis, and analysis of large volumes of historical OCT data for research datasets and real-world evidence generation.
- AI for Wet AMD Research Specialized AI research models for Wet AMD analysis, providing quantitative measurements of intraretinal cystoid fluid, diffuse edema, subretinal fluid, and serous RPE detachment. Includes Pathology Progression module for tracking feature changes across multiple visits. For research use only.
- AI for Geographic Atrophy Research Specialized AI research models for Geographic Atrophy (GA), providing characterization and visualization of OCT features including hypertransmission, RPE atrophy, neurosensory retinal atrophy, and ellipsoid zone changes. Includes GA Progression feature with overlap analysis, GA-fovea distance calculation, and macular coverage assessment. For research use only.
- Altris Education OCT Free educational mobile application for interactive education on OCT interpretation, designed to help eye care professionals learn and upgrade diagnostic skills. Used by 9,000+ ophthalmologists and optometrists worldwide.
Quantifiable outcome
- Analysis of 40,000 OCT scans for FinnGen research project
- +2 more outcomes
Companies that use Altris.AI
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Altris.AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability7 records
Feature8 records
Altris.AI partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- FinnGencoreLarge-scale research collaboration analyzing 40,000 OCT scans. Altris delivered highly valuable data enabling statistical insights that significantly accelerated FinnGen's research. Partnership demonstrates platform capability for pharma and genetic research applications.
- University of HelsinkicoreCollaborated with FinnGen and Altris on research project analyzing OCT scans. Partnership in academic research supporting large-scale retina research studies.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Altris.AI competitors and assessment
Company assessmentDirect peers
- Digital Diagnostics (IDx-DR): Digital Diagnostics builds FDA-cleared autonomous AI diagnostic systems for diabetic retinopathy and is a direct competitor in AI-driven retinal disease detection and OCT/fundus workflow analytics for eye-care clinics.
- Eyenuk: Eyenuk develops AI-based eye screening (EyeArt) for diabetic retinopathy and other retinal conditions, serving optometry and ophthalmology channels with a regulated, cleared product comparable to Altris's clinical proposition.
- RetinaLyze System: RetinaLyze offers AI-based retinal image analysis (fundus and OCT) for screening and biomarker detection in optometry/ophthalmology clinics, overlapping directly with Altris's vendor-neutral OCT analytics and biomarker quantification modules.
Emerging players
- AEYE Health: AEYE Health develops FDA-cleared AI for autonomous retinal disease screening (DR, AMD) from fundus and OCT images, targeting the same optometry/ophthalmology and primary-care screening workflows that Altris serves.
- Voxelcloud: VoxelCloud provides AI imaging analytics for ophthalmology (DR, AMD, glaucoma) and other specialties, overlapping with Altris in retinal disease AI and clinic-deployable imaging analytics.
- MedImaging AI: MedImaging AI is an emerging medical imaging AI vendor building AI tools for ophthalmology and radiology image triage, comparable in modality to Altris's vision-based clinical decision-support positioning.
Broad incumbents
- Topcon Healthcare: Topcon is one of the 9 major OCT manufacturers Altris supports and is increasingly embedding AI analytics (e.g., Imagenet/Heidelberg-style suites) into its own OCT hardware and viewing software, making it both a partner and a competitive threat.
- Heidelberg Engineering: Heidelberg Engineering is a leading OCT manufacturer (Spectralis platform) with its own AI/analytics software stack, competing for the OCT clinical workflow that Altris's vendor-neutral IMS targets.
- Carl Zeiss Meditec: Zeiss Meditec manufactures CIRRUS OCT systems and offers its own AI-augmented imaging analytics, representing both an integration partner for Altris and a major competitor for OCT-centric clinical workflows.
- Optos: Optos (Nikon) manufactures ultra-widefield retinal imaging devices and associated review software, an adjacent retinal imaging incumbent whose data Altris integrates and whose AI roadmap is a competitive variable.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Altris.AI social profiles
Digital presenceAltris.AI compliance and trust
Trust signalCompliance5 records
Altris.AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
Altris.AI leadership team
Management profileNumber of profiles
Profiles2 records
Altris.AI funding detail
Funding detailFunding overview
Funding rounds4 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Altris.AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Altris.AI
What does Altris.AI do?
Altris.AI develops and sells Altris IMS, an FDA 510(k)-cleared, vendor-neutral cloud-based image management system for Optical Coherence Tomography (OCT) scans. The platform applies deep learning AI models trained on 5 million OCT scans to detect 40+ retinal biomarkers and 30+ retinal pathologies, providing quantitative measurements, longitudinal progression tracking, and vendor-neutral support for scans from 9 major OCT manufacturers. It is offered as a SaaS subscription targeted at eye care clinics, optometry practices, pharmaceutical clinical trial sponsors, and academic research institutions.
Is Altris.AI a public or private company?
Altris.AI is a private company. It is classified as venture growth investor backed and is currently operating.
When was Altris.AI founded?
Altris.AI was founded in 2018. It employs 11 to 50 people.
Where is Altris.AI based?
Altris.AI is headquartered in Chicago, United States, in the North America region.
How does Altris.AI make money?
Two revenue lines are on record. Subscription-based SaaS are the primary driver. The others are enterprise Customization Services.
Who are Altris.AI's main competitors?
Direct peers on record are Digital Diagnostics (IDx-DR), Eyenuk and RetinaLyze System. Emerging players are AEYE Health, Voxelcloud and MedImaging AI. Broad incumbents are Topcon Healthcare, Heidelberg Engineering, Carl Zeiss Meditec and Optos.
Does Altris.AI have an API?
No public API is recorded for Altris.AI.
What industry is Altris.AI in?
Altris.AI's product category is Ophthalmology AI Imaging Software. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage). Its NAICS code is 5132 and its SIC code is 3826.